Zimmer Biomet - Showing Signs Of Life

The Value Investor Investing Group Leader Follow Summary Zimmer Biomet is seeing structural constant currency sales growth appear. This is driven by transformation factors, R&D, and M&A efforts. Earnings growth is lagging sales, but this hopefully should catch up soon. While growth is nice, it is welcomed given a substantial debt load, as growth and re-rating are the driving cases behind the stock and its potential. Looking for a helping hand in the market? Members of Value In Corporate Events get exclusive ideas and guidance to navigate any climate. Learn More » jetcityimage/iStock Editorial via Getty Images Shares of Zimmer Biomet Holdings, Inc. ( ZBH ) have recovered back to the $100 mark here again. Down on its knees to levels in the mid-$80s in March, I concluded that the appeal This article was written by The Value Investor 28.17K Followers Follow The Value Investor has a Master of Science with specialization in financial markets and a decade of experience tracking companies via catalytic company events. As the leader of the investing group Value In Corporate Events they provide members with opportunities to capitalize on IPOs, mergers & acquisitions, earnings reports and changes in corporate capital allocation. Coverage includes 10 major events a month with an eye towards finding the best opportunities. Learn more. Analyst’s Disclosure: I/we have a beneficial long position in the shares of ZBH either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.